Grufity logoGrufity logo
StocksFundsSearch Filings

Penumbra Inc Stock Research

PEN

306.50USD+1.60(+0.52%)Market Closed

Market Summary

USD306.50+1.60
Market Closed
0.52%

PEN Alerts

PEN Stock Price

PEN RSI Chart

PEN Valuation

Market Cap

11.7B

Price/Earnings (Trailing)

1.8K

Price/Sales (Trailing)

13.2

EV/EBITDA

270.57

Price/Free Cashflow

-207.64

PEN Price/Sales (Trailing)

PEN Profitability

Operating Margin

63.18%

EBT Margin

0.46%

Return on Equity

-0.2%

Return on Assets

-0.15%

Free Cashflow Yield

-0.48%

PEN Fundamentals

PEN Revenue

Revenue (TTM)

884.6M

Revenue Y/Y

18.39%

Revenue Q/Q

9.12%

PEN Earnings

Earnings (TTM)

6.5M

Earnings Y/Y

10.7K%

Earnings Q/Q

120.84%

Price Action

52 Week Range

114.87324.38
(Low)(High)

Last 7 days

-3.5%

Last 30 days

7.9%

Last 90 days

14.6%

Trailing 12 Months

116.0%

PEN Financial Health

Current Ratio

5.21

PEN Investor Care

Shares Dilution (1Y)

1.41%

Diluted EPS (TTM)

0.16

Peers (Alternatives to Penumbra)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
110.8B
19.0B
-8.78% 16.43%
46.98
6.01
8.73% 30.37%
107.5B
6.4B
4.05% 37.44%
81.96
16.72
8.89% -20.19%
74.1B
13.0B
-0.08% 27.20%
106.12
5.84
7.26% -32.95%
71.3B
18.8B
-6.73% -3.13%
44.09
3.79
-1.96% -15.83%
49.7B
5.5B
-6.18% -16.80%
33.38
9.03
2.68% -3.23%
MID-CAP
7.2T
557.2M
-1.64% 66.40%
82.2K
16.8K
86.42% 730.06%
11.7B
884.6M
7.85% 115.97%
1.8K
13.2
13.08% 200.12%
5.9B
1.1B
-8.20% -19.98%
34.14
5.75
11.20% 53.04%
3.6B
430.0M
-11.89% -12.63%
-34.73
8.45
26.13% 15.73%
1.7B
794.7M
-29.15% -60.56%
-8.43
2.16
7.73% -3556.34%
SMALL-CAP
1.6B
389.0M
-3.76% 82.19%
-10.63
4.18
44.08% 6.96%
1.2B
150.7M
-30.80% 0.49%
-21.65
7.87
40.31% 1.80%
1.1B
814.3M
-20.14% -16.22%
24.47
1.34
6.96% 121.89%
839.3M
239.8M
0.70% 0.15%
-22.16
3.5
-4.74% -31.15%

Financials for Penumbra

Income Statement (Last 12 Months)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Revenue4.4%884,636,000847,133,000829,928,000806,367,000782,281,000
Gross Profit4.4%558,861,000535,207,000522,227,000506,812,000491,463,000
Operating Expenses2.2%540,725,000529,125,000561,035,000542,273,000516,473,000
  S&GA Expenses2.7%461,896,000449,718,000447,588,000433,412,000409,433,000
  R&D Expenses8.1%81,924,00075,809,33373,381,333--
EBITDA237.2%28,213,000-20,557,000-18,402,000-9,410,000-
EBITDA Margin234.5%0.03-0.02-0.02-0.01-
Earnings Before Taxes353.4%17,648,0003,892,000-44,190,000-39,443,000-28,073,000
EBT Margin108.6%0.00-0.05-0.05-0.04-
Net Income423.7%6,481,000-2,002,000-30,512,000-19,391,000-6,473,000
Net Income Margin93.6%0.00-0.04-0.02-0.01-
Free Cahsflow16.8%-74,959,000-90,096,000-40,191,000-2,790,000-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets1.8%1,3951,3711,3221,3281,302
  Current Assets4.1%786756724718690
    Cash Equivalents35.5%95.0070.0055.0058.0068.00
  Inventory3.0%344334320296274
  Net PPE0.3%65.0065.0064.0063.0060.00
  Goodwill0.1%166166165166166
Liabilities-0.3%371372348358342
  Current Liabilities1.0%146145138146130
Shareholder's Equity2.6%999974970959-
  Retained Earnings19.5%52.0044.0040.0042.0046.00
  Additional Paid-In Capital1.6%979963947938919
Shares Outstanding0.5%38.0038.0038.0038.00-
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations31.7%-38.02-55.66-66.27-16.9119.00
  Share Based Compensation10.4%41.0037.0069.0067.0068.00
Cashflow From Investing-9.1%50.0055.0045.00-14.80-9.11
Cashflow From Financing34.6%16.0012.009.007.001.00

Risks for PEN

What is the probability of a big loss on PEN?

97.3%


Probability that Penumbra stock will be more than 20% underwater in next one year

58.5%


Probability that Penumbra stock will be more than 30% underwater in next one year.

18.9%


Probability that Penumbra stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does PEN drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Penumbra was unfortunately bought at previous high price.

Drawdowns

Returns for PEN

Cumulative Returns on PEN

28.4%


7-Year Cumulative Returns

14.3%


5-Year Cumulative Returns

21.8%


3-Year Cumulative Returns

What are the long-term rolling returns for PEN?

FIve years rolling returns for Penumbra.

Annualized Returns

Which funds bought or sold PEN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-23
Toroso Investments, LLC
added
233
940,000
1,236,000
0.02%
2023-05-23
Brookfield Corp /ON/
reduced
-78.06
-2,590,440
981,825
-%
2023-05-22
AMERIPRISE FINANCIAL INC
reduced
-1.21
2,659,110
13,848,100
-%
2023-05-22
Raleigh Capital Management Inc.
new
-
14,213
14,213
0.01%
2023-05-18
NEW YORK STATE COMMON RETIREMENT FUND
reduced
-6.5
2,910,000
19,891,000
0.03%
2023-05-18
JPMORGAN CHASE & CO
added
4.94
7,199,000
30,077,000
-%
2023-05-18
TITLEIST ASSET MANAGEMENT, LLC
new
-
250,821
250,821
0.05%
2023-05-17
Thrivent Financial for Lutherans
reduced
-0.92
543,000
2,793,000
0.01%
2023-05-17
Advisory Services Network, LLC
new
-
12,262
12,262
-%
2023-05-17
Sunbelt Securities, Inc.
new
-
5,819
5,819
-%

1–10 of 39

Latest Funds Activity

Are funds buying PEN calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own PEN
No. of Funds

Penumbra News

MarketBeat
American International Group Inc. Lowers Position in Penumbra, Inc ....
MarketBeat,
10 hours ago
Yahoo Eurosport UK

Schedule 13G FIlings of Penumbra

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2023
capital research global investors
6.1%
2,321,719
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
9.13%
3,467,792
SC 13G/A
Jan 23, 2023
blackrock inc.
11.6%
4,422,738
SC 13G/A
Feb 11, 2022
capital research global investors
7.4%
2,770,020
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Feb 04, 2022
wellington management group llp
0.00%
14
SC 13G/A
Feb 03, 2022
blackrock inc.
9.0%
3,356,220
SC 13G/A
Feb 16, 2021
capital research global investors
8.9%
3,248,192
SC 13G
Feb 10, 2021
vanguard group inc
8.42%
3,057,710
SC 13G/A

PEN Fair Value

Recent SEC filings of Penumbra

View All Filings
Date Filed Form Type Document
May 16, 2023
4
Insider Trading
May 15, 2023
4
Insider Trading
May 11, 2023
144
Notice of Insider Sale Intent
May 03, 2023
4
Insider Trading
May 02, 2023
10-Q
Quarterly Report
May 02, 2023
8-K
Current Report
May 01, 2023
144
Notice of Insider Sale Intent
Apr 19, 2023
ARS
ARS
Apr 19, 2023
DEF 14A
DEF 14A
Apr 19, 2023
DEFA14A
DEFA14A

Latest Insider Trading transactions for PEN

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-05-15
Roberts Johanna
sold (taxes)
-531,585
314
-1,688
evp, gen. counsel & secretary
2023-05-12
Roberts Johanna
acquired
14,370
22.04
652
evp, gen. counsel & secretary
2023-05-12
Roberts Johanna
sold
-479,505
319
-1,500
evp, gen. counsel & secretary
2023-05-11
Elsesser Adam
acquired
74,911
7.75
9,666
ceo and president
2023-05-11
Elsesser Adam
sold
-3,078,860
318
-9,666
ceo and president
2023-05-01
Bose Arani
sold
-1,429,330
285
-5,000
-
2023-04-15
Roberts Johanna
sold (taxes)
-51,914
277
-187
evp, gen. counsel & secretary
2023-04-03
Sarna Surbhi
sold
-7,738
276
-28.00
-
2023-04-03
Roberts Johanna
sold
-166,882
278
-600
evp, gen. counsel & secretary
2023-04-03
Bose Arani
sold
-1,377,930
275
-5,000
-

1–10 of 50

Adam Elsesser
3800
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

PEN Income Statement

2023-03-31
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]  
Revenue$ 241,398$ 203,895
Cost of revenue90,32676,477
Gross profit151,072127,418
Operating expenses:  
Research and development19,98620,564
Sales, general and administrative123,078110,900
Total operating expenses143,064131,464
Income (loss) from operations8,008(4,046)
Interest income (expense), net554(47)
Other income (expense), net90(1,011)
Income (loss) before income taxes8,652(5,104)
Provision for (benefit from) income taxes90(5,183)
Net income$ 8,562$ 79
Net income per share:  
Basic (in dollars per share)$ 0.22$ 0.00
Diluted (in dollars per share)$ 0.22$ 0.00
Weighted average shares outstanding:  
Basic (in shares)38,186,34237,646,122
Diluted (in shares)39,075,38838,708,657

PEN Balance Sheet

2023-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 94,688$ 69,858
Marketable investments104,409118,172
Accounts receivable, net of allowance for credit losses of $937 and $862 at March 31, 2023 and December 31, 2022, respectively207,364203,384
Inventories344,042334,006
Prepaid expenses and other current assets35,98730,279
Total current assets786,490755,699
Property and equipment, net65,22465,015
Operating lease right-of-use assets189,839192,636
Finance lease right-of-use assets32,56933,323
Intangible assets, net78,66981,161
Goodwill166,161166,046
Deferred taxes65,17364,213
Other non-current assets11,17312,793
Total assets1,395,2981,370,886
Current liabilities:  
Accounts payable28,19926,679
Accrued liabilities105,869106,300
Current operating lease liabilities10,30310,033
Current finance lease liabilities1,9571,920
Total current liabilities146,328144,932
Non-current operating lease liabilities196,837198,955
Non-current finance lease liabilities24,42324,865
Other non-current liabilities3,2413,276
Total liabilities370,829372,028
Commitments and contingencies
Stockholders’ equity:  
Common stock3838
Additional paid-in capital978,826963,040
Accumulated other comprehensive loss(6,861)(8,124)
Retained earnings52,46643,904
Total Penumbra, Inc. stockholders’ equity1,024,469998,858
Total liabilities and stockholders’ equity$ 1,395,298$ 1,370,886